Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top California based Founder operating in the Biotechnology space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Anne Wojcicki
Co-Founder and CEO of 23andMe
Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world’s largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne’s leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.
Follow Anne Wojcicki:
About 23andMe, The Brin Wojcicki Foundation: 23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Lin Jixun
Founder & CEO of ACON Laboratories
Lin Jixun has served as our director since 2008 and is the founder and chief executive officer of ACON Laboratories Inc., a worldwide leading manufacturer of high-quality rapid diagnostic test products. Mr. Lin founded ACON Laboratories Inc. in 1995 and serves on the company’s board of directors. He also serves on the board of directors for ACEA BioSciences Inc., a company providing innovative cell-based assay systems for basic life science research and drug discovery. Mr. Lin received his Ph.D. in microbiology and immunology from the Medical University of South Carolina and a Bachelor of Medicine from Zhejiang Medical University.
Follow Lin Jixun:
About ACON Laboratories: ACON Laboratories is a biotechnology firm that offers medical diagnostic and healthcare products.
Jennifer Doudna
Co-Founder of Mammoth Biosciences
As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Dr. Jennifer Doudna and her colleagues rocked the research world in 2012 by describing a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria. This technology, called CRISPR-Cas9, has opened the floodgates of possibility for human and non-human applications of gene editing, including assisting researchers in the fight against HIV, sickle cell disease and muscular dystrophy. Doudna is an investigator with the Howard Hughes Medical Institute, senior investigator at Gladstone Institutes, and the Executive Director of the Innovative Genomics Institute. She is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. Doudna is also a Foreign Member of the Royal Society and has received numerous other honors including the Breakthrough Prize in Life Sciences, the Japan Prize, and the Kavli Prize. Doudna’s work led TIME to recognize her as one of the “100 Most Influential People” in 2015, and she is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing. She is a vocal proponent of its responsible use, first calling for a moratorium on using CRISPR technology to make permanent changes to the human germline in 2015.
Follow Jennifer Doudna:
About Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, Scribe Therapeutics, University of California Berkeley: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Trevor Martin
Co-Founder and CEO of Mammoth Biosciences
As co-founder and CEO of Mammoth Biosciences, Trevor Martin is focused on creating the world’s first CRISPR-based platform for disease detection, taking impactful CRISPR technology out of the lab and into the hands of doctors and consumers. Prior to co-founding Mammoth, Trevor completed his PhD in Biology at Stanford University, where he worked at the intersection of statistics and genetics. In addition to having taught a course in Statistics at Stanford, Trevor has penned educational guides for university courses across the globe. His work has been featured in outlets like FiveThirtyEight and The Atlantic.
Follow Trevor Martin:
About Mammoth Biosciences: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Raja Dhir
Co-Founder and Co-CEO of Seed Health
Raja Dhir is a life sciences entrepreneur and Co-Founder of Seed Health, a venture-backed microbiome company pioneering the application of bacteria for both human and planetary health. He leads Seed’s R&D, academic collaborations, technology development, clinical trial design, supply chain, and intellectual property strategy. Together with Dr. Jacques Ravel, he Co-Chairs Seed’s Scientific Advisory Board–an interdisciplinary group of scientists and doctors who lead research teams and teach at institutions including the teaching hospital of Harvard Medical School and the Trial Innovation Unit of Mass. General Hospital (MGH). Raja has designed clinical trials with leading academic institutions including the teaching hospital of Harvard Medical School and the Trial Innovation Unit of Mass. General Hospital (MGH). Raja has unique expertise translating scientific research for product development with a track record that includes patented inventions to stabilize sensitive compounds to improve alpha-diversity of the gut microbiome (derived from micro-algae) and most recently, the co-invention of microbial technologies to protect honeybee populations (Apis mellifera) from neonicotinoid pesticides and pathogen colonization. His work also includes biofermentation and scale-up for both facultative and strict anaerobic organisms. Raja has negotiated multiple joint-ventures, strategic partnerships, technology transfer and licensing agreements with publicly traded companies (NYSE, LSE) and academic institutions (Harvard Medical School, UCLA). To date, entities he has co-founded own the rights to 15+ patents and research emerging from $25MM+ of non-dilutive funding over 10+ years from the Bill and Melinda Gates Foundation and National Institute of Health (NIH). Raja serves on the Editorial Board for the scientific journal, Microbiome. He is a member of the Microbiome Think Tank at Mass. General Hospital (MGH) and sits on the Advisory Committee for the International Scientific Association of Probiotics and Prebiotics (ISAPP). Raja is also a Director and Co-Chair of the Scientific Advisory Board for Micropia, a $20MM microbial ecology / education platform and the world’s first museum dedicated to microbes.
Follow Raja Dhir:
About Seed Health: Seed Health is a microbial company that focuses on therapeutics, consumer health innovations, and environmental solutions.
Ara Katz
Co-Founder and Co-CEO of Seed Health
Ara Katz is the Co-Founder and Co-CEO of Seed Health, a microbial sciences company pioneering the application of bacteria to impact human and planetary health. She has worked at the intersection of technology, consumer, design, and media is now working to steward a new standard in probiotics and how science is communicated to change how we discern evidence from evangelism to make the most informed choices for our bodies, our health, and our world. Ara previously co-founded and served as CMO of mobile commerce marketplace, Spring (backed by LMVH, sold to ShopRunner), and was on the founding team of social commerce company, BeachMint (sold to Conde Nast), where she launched six direct-to-consumer, influencer subscription brands. She is an angel investor and advisor in companies such as mindbodygreen, Stadium Goods (recently sold to FarFetch), RXDefine, women’s healthcare startup, Mahmee, and new biomaterials company, C16. Ara has been a fellow at the MIT Media Lab’s Center for Future Storytelling and CCA’s Design MBA program, was named in Marie Claire’s “The New Guard: The 50 Most Influential Women in America”, listed on Business Insider’s “Silicon Alley Top 100” and “36 Rockstar Women in NYC Tech”, and Create + Cultivate’s 100 List for STEM.
Follow Ara Katz:
About Seed Health: Seed Health is a microbial company that focuses on therapeutics, consumer health innovations, and environmental solutions.
Sam Santhosh
Founder Chairman & Global CEO of MedGenome
Sam Santhosh is the Founder and CEO of MedGenome. He has been an entrepreneur, with over 20 years of experience in the software industry. Currently, he is at the helm of affairs as CEO and promoter of MedGenome Labs Pvt Ltd. Sam sits on the board of a number of companies, both in the US and India. In this role he advises, guides and mentors companies to help them grow and realize their true potential. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992 – Feb 2012. He founded Calsoft in 1992 and under Sam’s vision, Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft Public and the company is listed the in Indian Stock Exchanges. Sam oversaw the growth of Calsoft in all key areas – Finance, Strategy, Customer Acquisition, and inorganic growth through eight acquisitions including companies in the U.S, UK, Japan, and India. He has been constantly retooling himself and has attended various training programs in different U.S universities including MIT. In 2010, he completed the Executive Education program at the Singularity University in Sunnyvale, California. Sam has an engineering degree and an MBA (majoring in Management Information Systems) from India’s premier institute, IIM Calcutta.
Follow Sam Santhosh:
About Agrigenome, MedGenome: MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Joshua Nixon
CTO and Co-Founder of Prime Roots
Follow Joshua Nixon:
About Prime Roots: Prime Roots is celebrating the culture of meat by reimagining protein itself.
Kimberlie Le
CEO and Co-Founder of Prime Roots
Follow Kimberlie Le:
About Prime Roots: Prime Roots is celebrating the culture of meat by reimagining protein itself.
Ross Bundy
Co-Founder, Chief Entrepreneur, Chief Production Office of Cardea Bio
A founding member of Nanomed and the company’s CEO, Ross is a graduate of UCSD with an MBA from SDSU. Ross’s passion is precision execution, and he applies this to driving company direction and operations, developing strategic collaborations and partnerships, and raising capital funding. Ross brings business development, supply chain, finance, and operations expertise from 13 years of experience in industries ranging from consumer goods to defense manufacturing to financial services. At Bumble Bee Foods, Ross created and implemented cross-functional supply chain procedures that reduced processing hours while improving scheduling accuracy and decreasing cost. Prior to Bumble Bee at General Dynamics, Ross identified and negotiated business development projects that gained the company new opportunities in alternative energy, commercial construction, and heavy tool manufacturing. At UBS Financial Services, Ross created financial models to estimate future growth rates. Ross brings a demonstrated track record of successful implementation and a well-rounded background to his role as CEO of Nanomed.
Follow Ross Bundy:
About Cardea Bio: Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Kiana Aran
Co-Founder & Chief Scientific Officer of Cardea Bio
Kiana Aran is a Co-Founder and Chief Scientific Officer at Cardea Bio.
Follow Kiana Aran:
About Cardea Bio: Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Roy Paxton Yih
Co-Founder and CEO of Biocare Medical
Roy Paxton Yih, BS, MA, co-founded Biocare Medical, LLC in 1997 and serves as its Chief Executive Officer and President. Roy Yih served as a Director of Sales & Marketing at Biocare Medical LLC. Roy Yih is primarily involved at sales, marketing and business development activities. He holds a BS Degree in Biochemistry from U.C. Davis and an MBA from the University of Santa Clara.
Follow Roy Paxton Yih:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
Cary Gunn
CEO & Founder of Genalyte
Dr. Cary Gunn — who drives Genalyte’s strategic vision, direction, culture and success — has been blazing trails in the technology community for almost 30 years. Prior to leading Genalyte, Cary served as co-founder and chief technical officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in applied physics and organic chemistry from the United States Air Force Academy and his PhD in electrical engineering from the California Institute of Technology (Caltech). At Genalyte, Cary is proud to pioneer technology that has “a positive impact on life and human health.”
Follow Cary Gunn:
About Genalyte: Genalyte is a life sciences company developing and commercializing innovative next-generation multiplexing technology.
Zhen Li
Founder, President & CEO of ADARx Pharmaceuticals
Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.
Follow Zhen Li:
About ADARx Pharmaceuticals: ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Osman Kibar
CEO & Founder of Biosplice Therapeutics
Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas were acquired by Titan and assets relating to thermal management of microprocessors by Intel. He was a Vice President at Pequot Capital’s venture capital and private equity team. Dr. Kibar received his M.S. and Ph.D., specializing in Biophotonics and Optoelectronics, from University of California, San Diego, a B.S. in Electrical Engineering from Caltech and a B.A. in Mathematical Economics from Pomona College.
Follow Osman Kibar:
About Biosplice Therapeutics: Biosplice Therapeutics is in the medical research and development for tissue-level regeneration.
Matthew Milford
Co-Founder of Genetic Foresight
Matthew Milford is the Co-Founder at Foresight.
Follow Matthew Milford:
About Foresight Mental Health, Genetic Foresight: Genetic Foresight is personalizing medicine to enable safer and more effective prescriptions.
Mickey Kertesz
President, CPO & Co-Founder of Karius
Kertesz co-founded Karius in 2014 to bring the pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Prior to that, he was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Dr. Kertesz earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to complete his postdoctoral work in bioengineering at Stanford University, where he developed novel methods for investigating the genetic diversity of human viruses.
Follow Mickey Kertesz:
About Karius: Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Tim Blauwkamp
Chief Scientific Officer, Co-Founder of Karius
Follow Tim Blauwkamp:
About Karius: Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Charles Roberts
Co-Founder, Chief Growth Officer of Freenome
A clinician by training, Charlie is Freenome’s Chief Partnership Officer, focusing on mid- and longer-term relationships that will help define the company’s future directions and revenues and works closely with the business development team in managing corporate client accounts and institutional collaborations. Prior to co-founding Freenome, Charlie co-founded a company that uses circulating cell-free (cf)DNA from maternal blood samples to diagnose chromosomal abnormalities during pregnancy. The resulting in-vitro diagnostic, IONA, has been marketed successfully across Europe and the Middle East. Charlie studied medicine and neuropsychology in the UK, earning a Masters degree from Oxford with a focus on immunotherapy. He has worked in some of the UK’s leading oncology centers, including the Royal Marsden.
Follow Charles Roberts:
About Freenome, Relation Therapeutics: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Riley Ennis
Co-Founder and COO of Freenome
Riley is a Thiel Fellow who created a cancer vaccine with his previous company Immudicon as Co-Founder & Chair. Co-Founder, COO at Freenome.
Follow Riley Ennis:
About Freenome, Immudicon, Oncolinx, The Thiel Foundation: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Rene Bharti
Founder & Executive Chairman of Future Fertility
Rene has held several key roles in both public and private companies, including those in the resource, technology and entertainment industry. Rene Bharti co-founded ARHT Media, along with legendary singer Paul Anka, with the aim of creating the worlds most lifelike digital humans to conduct e-commerce in a unique and viable platform. Rene Bharti holds a Bachelor of Commerce (Honors) from Queens University.
Follow Rene Bharti:
About Future Fertility, Spend: Future Fertility is a provider of artificial intelligence tools for reproductive medicine.
Martin G. Reese
Co-Founder, Chief Executive Officer & President of Fabric Genomics (formerly Omicia)
Martin Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Omicia, Martin Reese served as Vice President of Discovery Informatics for ValiGen. Prior to this, Martin Reese co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin Reese developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career Martin Reese has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin Reese developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.
Follow Martin G. Reese:
About Fabric Genomics (formerly Omicia): Global healthcare platform for genomics-driven precision medicine. Fabric’ proven AI algorithms power genomic insights.
John Stuelpnagel
Co-Founder & Chairman of Fabric Genomics (formerly Omicia)
Dr. John Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function. John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008. Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Follow John Stuelpnagel:
About Ariosa Diagnostics, Fabric Genomics (formerly Omicia): Global healthcare platform for genomics-driven precision medicine. Fabric’ proven AI algorithms power genomic insights.
Cheng Liu
Founder, CEO of Eureka Therapeutics
Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.
Follow Cheng Liu:
About Eureka Therapeutics: Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Frank Lee
CEO & Founder of Virus Geeks Inc.
Follow Frank Lee:
About CarSnatch, Virus Geeks Inc.: SaaS, Mobile App, BioHealth, Information Technology
Hesaam Esfandyarpour
Founder and CEO of Genapsys
Hesaam is the Founder and CEO of GenapSys Inc. He is an inventor of electronic DNA sequencing, a technology he developed during his PhD work at Stanford. Hesaam has dedicated the past decade of his life to the development of this novel DNA sequencing technology, which has at its core the convergence of multiple fields of science – engineering, chemistry, biology, and computing. Hesaam incubated the technology at the Stanford Genome Technology Center for a period of six years before securing licenses to the IP and incorporating GenapSys in January of 2010. He has grown GenapSys from just a handful of employees working out of Menlo Labs incubator space, to over 50 employees across seven functional teams. In 2012, Hesaam partnered GenapSys with StartX, an accelerator for the development of Stanford’s top entrepreneurs. He has raised approximately $50M for GenapSys in Seed, Series A, and Series B rounds of financing. Hesaam holds a PhD and MS in Electrical Engineering, and MSc Management degree, all from Stanford University. He earned his BS in Electrical Engineering with Honors from Sharif University of Technology in Tehran, Iran. When he is not at GenapSys HQ (which is rare!) you can find Hesaam spending time outdoors, hiking or spending time with family and friends. He is also a great lover of poetry, his favorite of which are poems by the Persian poet Saa’di.
Follow Hesaam Esfandyarpour:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Oguzhan Atay
Co-Founder of BillionToOne
Oguzhan is responsible for implementing BillionToOne’s vision and for all day-to-day management decisions. During his PhD at Stanford, he has combined machine learning and genetics to solve problems in cell biology. His PhD research has been featured as Cover Article in Cell Systems, and his work has been published in high-impact peer-reviewed journals, including Cell and Journal of Cell Biology.
Follow Oguzhan Atay:
About BillionToOne: BillionToOne is a precision diagnostics company that makes molecular diagnostics accurate, efficient, and accessible for all.
Aditya Rajagopal
Co-Founder & CTO of ChromaCode
Aditya Rajagopal is the Founder & CTO of ChromaCode, Inc, and a Visiting Associate in Electrical Engineering at Caltech. He completed his education at Caltech (B.S., M.S., and Ph.D.) and has fifteen years of experience in medical engineering, microfluidics, nanotechnology and bioengineering. Aditya Rajagopal’s research has resulted in innovative technology developments and he has authored over 50 patents and publications. He is the recipient of numerous honors including the Caltech Grubstake Award in 2017 and the Caltech Innovation Initiative (CI2) in 2014 and 2015.
Follow Aditya Rajagopal:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Greg Gosch
Co-Founder, President, & CEO of ChromaCode
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer’s disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Follow Greg Gosch:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Axel Scherer
Co-Founder of ChromaCode
Axel is a ChromaCode founder and the Bernard A. Neches Professor of Electrical Engineering, Applied Physics and Physics at Caltech. He joined the Electrical Engineering department at Caltech in 1993, after working in the Microstructures Research Group at Bellcore. Axel’s group works on micro- and nanofabrication of optical, magnetic and fluidic devices. He has co-authored over 300 publications and holds over 70 patents in the fields of optoelectronics, microfluidics, and new nanofabrication techniques. Axel has co-founded three high-technology companies and built a state of the art laboratory for advanced high-resolution lithography and pattern transfer at Caltech. He has pioneered microcavity lasers such as vertical cavity surface emitting lasers, microdisk lasers and photonic crystal lasers in many materials systems. Presently, his group works on integration of microfluidic chips with electronic, photonic and magnetic sensors. His group has also developed silicon nanophotonics and surface plasmon enhanced light emitting diodes, and has perfected the fabrication and characterization of ultra-small structures by lithography and electron microscopy. He received hi PhD in 1985 from the New Mexico Institute of Mining and Technology.
Follow Axel Scherer:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Kevin Kinsella
Managing Member, Founder of Avalon Ventures
Kevin Kinsella founded Avalon in 1983. He has specialized in the formation, financing and/or development of more than 60 early-stage companies, including: Athena Neurosciences (acquired by Elan Corporation, plc (NYSE: ELN)); Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX); Sequana Therapeutics (merged with Arris to form AXYS Pharmaceuticals, acquired by Celera Genomics (NYSE: CRA)); Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX); Synaptics, Inc. (Nasdaq: SYNA); Vocera Communications; and Sytera Ophthalmics Inc. (acquired by Sirion Therapeutics). Mr. Kinsella was the founding chairman of Athena Neurosciences, Aurora Biosciences Corporation, Landmark Graphics, NeoRx, Onyx Pharmaceuticals, Inc., Synaptics, Vertex Pharmaceuticals, X-Ceptor and Sequana Therapeutics. Prior to founding Avalon, Mr. Kinsella worked for Solar Turbines International (Caterpillar Tractor) where he was in charge of all international joint ventures, barter and counter-trade. Previously, he was an advisor to the Peruvian government in National Nutrition Planning, ran a technology exchange program between the U.S. and Latin America based in Mexico City, and taught algebra at the American High School in Beirut, Lebanon. He was also a guest op-ed columnist for the Boston Herald American. Mr. Kinsella is a graduate of the Massachusetts Institute of Technology (“MITâ€) with a Bachelor of Science degree in management, with minors in electrical engineering and political science. He holds a Master of Arts degree in international relations from the Johns Hopkins School of Advanced International Studies (“SAISâ€) and conducted post-graduate work in political economy on a Rotary International Fellowship at the University of Stockholm, Sweden. He is a member of the Circumnavigators Club, an elite group of explorers who have gone around the world in a continuous trip using multiple modes of transport. Mr. Kinsella is a Life Sustaining Fellow at MIT and a member of the Dean’s Advisory Council at SAIS. He is the largest individual producer of the Tony Award-winning hit Broadway musical, [url=http://www.theatreticketscheap.com/jersey-boys/]Jersey Boys[/url], and the partner of Rhino Records (Time Warner) in producing the Grammy Award-winning Jersey Boys Original Cast Recording, which has gone Platinum (selling over 1 million copies). Mr. Kinsella is a member of the Boards of Directors of Amira, Anaptys, and InCode, all Avalon portfolio companies. Mr. Kinsella is a member of the Council on Foreign Relations and a member of the Broadway League (Tony voter). He and his wife, Tamara, own Kinsella Estates Winery (Healdsburg, California), whose first vintage of premium Dry Creek cabernet sauvignon will be released in 2011.
Follow Kevin Kinsella:
About Avalon Ventures: Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.
Michael M. Henson
Founder of Endologix
Michael Henson is a co-founder of Reverse Medical Corporation, was named “Corporate Director of the Year” among all Orange County executives in 2000. He founded the MedFocus Fund with the Japan Asia Investment Company, Ltd., one of the largest venture capital firms in Japan and a group of international limited investors from around the world. Mr. Henson has participated in the formation of more than seventeen medical technology and pharmaceutical firms. He currently serves on the Board of Directors of nine medical firms, and is Chairman of seven of the companies. Mr. Henson has founded or served as Chief Executive Officer and Chairman of the Board for many successful emerging health care, medical device or biotechnology firms. Mr. Henson has successfully taken a number of companies public via the IPO process and negotiated the successful acquisition of several emerging companies to large multi-national healthcare firms.
Follow Michael M. Henson:
About Endologix, Interventional Spine, Reverse Medical: Endologix is a developer and manufacturer of minimally invasive treatments for aortic disorders.
Anna Skaya
CEO & Founder of Basepaws
Anna Skaya is the founder and CEO of Basepaws, a provider of low-cost pet genomic products and services. Most recently, Anna was a partner and COO at breakupbuddy. She was also the founder and former CEO of Visual DNA. Prior to Visual DNA, Anna was a CEO at Groupon Russia.
Follow Anna Skaya:
About Basepaws: Pet genetics & health monitoring.
Deepak Thomas
Co-Founder & CEO of Phil
Mr. Deepak Thomas Founded Phil, Inc. and serves as its Chief Executive Officer. After a particularly frustrating experience at a chain drug store, Mr. Thomas sat down and did the math on the number of hours he had spent standing in line for his prescriptions. When he realized that he had spent over 500 hours standing in line at drug stores, he decided to spend at least 500 hours trying to build a better experience before founding Phil, Inc. Prior to this, he held product and general management roles at eBay, Shutterfly, Match.com and Oracle.
Follow Deepak Thomas:
About Phil: Phil is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to patient access solutions
Puran Singh
Co-Founder/Head of Engineering of Phil
Follow Puran Singh:
About Phil: Phil is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to patient access solutions
Sasan Amini
Co-Founder and CEO of Clear Labs
Sasan combined his academic expertise and passion for healthy living when he co-founded Clear Labs with a mission to set a new paradigm for food safety and quality. Prior to serving as the CEO of Clear Labs, he worked in the Advanced Research department at Illumina. Sasan earned his PhD in Genomics from Princeton and holds multiple patents and publications in the field.
Follow Sasan Amini:
About Clear Labs: Clear Labs is a provider of a fully-automated sequencing platform for turnkey diagnostics.
Chris Wheeler
Co-Founder & CEO of Diagnose Early
Follow Chris Wheeler:
About Diagnose Early, WISC Partners: Diagnose Early provides detection technologies for cancer, neurological, and infectious diseases.
Bill Cherman
Co-Founder and Chairman of Repair Biotechnologies
Bill is co-founder and Chairman of Repair Biotechnologies. He is a Partner at Front Seat Capital, where he leads investments in biotech and blockchain. Previously, he was a consultant at McKinsey & Company. Bill is a student of the Master of Biotechnology Enterprise and Entrepreneurship at Johns Hopkins University, and has a B.A. in Economics from PUC-Rio.
Follow Bill Cherman:
About Repair Biotechnologies: Repair Biotechnologies is a biotechnology company with the mission to develop and bring to the clinic therapies.
Prashant Mali
Co-Founder of Shape Therapeutics
Prashant Mali is a co-Founder at Shape Therapeutics with Francois Vigneault and John Suliman. Prashant has been an Assistant Professor of Bioengineering at the University of California, San Diego since 2014. His research focuses in the fields of synthetic biology and regenerative medicine, with a long-term focus on developing tools for enabling gene and cell based human therapeutics.
Follow Prashant Mali:
About Seven Therapeutics, Shape Therapeutics: A biotechnology company developing RNA technologies to shape the future of gene therapy
Tim Sweeney
Co-Founder & CEO of Inflammatix
Tim Sweeney, MD, PhD is the co-Founder & CEO of Inflammatix, Inc., which focuses on using robust informatics and machine learning to derive novel HostDx™ diagnostics based on ‘reading’ patterns in the immune system. Inflammatix’s first tests are focused on diagnosing acute bacterial and viral infections and sepsis. The company is funded by Khosla Ventures, Stanford-StartX Fund and the U.S. government’s DARPA program. Tim Sweeney completed his MD and PhD at Duke University, after which he was a surgery resident at Stanford. While training as a surgeon, he became frustrated with the limitations of current diagnostic tools for infection. During his residency, he completed a postdoctorate MS in Biomedical Informatics, mentored by Dr. Purvesh Khatri. Together they designed the custom informatics algorithms for sifting through heterogeneous ‘big data,’ which formed the core technology on which Inflammatix is based.
Follow Tim Sweeney:
About Inflammatix: Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by reading the immune system.
Tarek Tabsh
Co-Founder of Oxford Cannabinoid Technologies
Follow Tarek Tabsh:
About Alta Flora, Arcview Group, New Amsterdam Naturals, Oxford Cannabinoid Technologies, Province Brands of Canada: OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.
Hira Thapliyal
Founder, President & CEO of Aneumed
Hira Thapliyal is the founder, president & CEO of AneuMed, Inc.AneuMed is an early stage company engaged in developing devices for the treatment of various ailments affecting the human cardiovascular system. Prior to that, Dr. Thapliyal was the co-founder, president & CEO of VytronUS, Inc., a development stage company working on products for treatment of cardiac arrhythmias. Currently, VytronUS is conducting human clinical trials for its products. Before that, Hira was the co-founder, president & CEO of Tescient, Inc. Tescient was focused in developing products aimed at tissue regeneration and wound healing in human body. Tescient prototype products did not perform well in early animal tests, so Dr. Thapliyal closed Tescient and returned 60% of the invested capital back to the investors. Prior to Tescient, Dr. Thapliyal co-founded ArthroCare Corp (NASDAQ: “ARTC”) in 1993, and served its president & CEO and took the company public in 1996. ArthroCare was recently acquired by Smith & Nephew for $1.7 billion. ArthroCare markets products in the field of arthroscopy, ENT, spine, skin, and wound healing. Before ArthroCare, Hira served as the president of MicroBionics, a company developing products for continuous measurements of blood parameters in critically ill patients. Before MicroBionics, Hira co-founded and served as the president of CardioVascular Imaging Systems (NASDAQ: “CVIS”) which developed and marketed an ultrasound based imaging system, Intravascular Ultrasound (‘IVUS’), for the human blood vessels. CVIS went public and was later acquired by Boston Scientific (“BSX”). Prior to that, Hira served as the Vice President of Devices for Vascular Interventions (DVI) which developed and marketed products for removal of plaque form inside on the diseased arteries. DVI was acquired by Eli Lilly in 1989. Prior to DVI, Dr. Thapliyal held engineering and management positions at Oximetrix, Inc., Amdahl, and Corning. Dr. Thapliyal holds a BSEE degree from Washington State University, a MSEE from University of Idaho, and a PhD degree in Materials Science & Engineering from Cornell University. Hira has received numerous awards, and currently serves as an advisor to the Stanford-India Biodesign Program at Stanford University. Dr. Thapliyal also served as a judge for the Entrepreneur of the Year award at Earnst & Young. Dr. Thapliyal currently holds over 193 issued US and International patents for various medical devices.
Follow Hira Thapliyal:
About Aneumed, VytronUS: Aneumed is a biotechnology company based in California, United States.
Jenny Rooke
Founder & Managing Director of Genoa Ventures
Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.
Follow Jenny Rooke:
About Genoa Ventures: Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.
Harry Gruber
CEO, Co-Founder & President of Tocagen
Harry E. Gruber, M.D., one of the pioneers in gene therapy, co-founded Tocagen and led the company as chief executive officer before assuming the role of president, research and development in November 2016 and president, science and innovation in October 2017. He has been a member of the board of directors since August 2007. Dr. Gruber served as our chief executive officer from August 2007 to November 2016 and served as chairman of our board of directors from August 2007 to October 2014. Dr. Gruber is a co-founder of Tocagen and has been the co-founder and/or co-inventor of key technology for the following publicly held companies: Viagene Inc., a gene therapy company acquired by Novartis Pharmaceuticals; Gensia Inc., a biopharmaceutical company acquired by Teva Pharmaceuticals Industries, Ltd.; INTERVU Inc., a technology company acquired by Akamai Technologies, Inc.; Kintera, Inc., a technology company acquired by Blackbaud. He is the author of more than 100 original scientific articles and an inventor on more than 100 issued and pending patents. Dr. Gruber holds a medical degree and bachelor’s degree from the University of Pennsylvania and trained in Internal Medicine, Biochemical Genetics and Rheumatology/Immunology at the University of California, San Diego, where he subsequently joined the medical school faculty until founding Gensia Inc.
Follow Harry Gruber:
About Tocagen: Tocagen is a biopharmaceutical company developing gene therapy products for the treatment of cancer.
Igor Khandros
Co-Founder of Berkeley Lights
Igor Y. Khandros Co-Founded Berkeley Lights, Inc. and serves as its Chief Executive Officer. Igor Khandros served as an Advisor of FormFactor Inc. Igor Khandros founded Formfactor Inc. and served as its Executive Chairman. Igor Khandros served as the Chief Executive Officer of Formfactor and also served as its President Igor Khandros served as the Vice President of Development of Tessera Technologies Inc., that he co-founded. he was employed at the Yorktown Research Center of IBM Corporation as a Member of the Technical Staff and a Manager. Igor Khandros was employed at ABEX Corporation as a Research Metallurgist and a Manager, and he served as an Engineer at the Institute of Casting Research in Kiev, Russia. Igor Khandros has been a Director of FormFactor Inc., Igor Khandros holds an M.S. equivalent degree in Metallurgical Engineering from Kiev Polytechnic Institute in Kiev, Russia, and a Ph.D. in Metallurgy from Stevens Institute of Technology.
Follow Igor Khandros:
About Berkeley Lights, Nutcracker Therapeutics: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Joe Bondy-Denomy
Co-Founder of Acrigen Biosciences
Joe Bondy-Denomy is a Co-Founder of Acrigen Biosciences.
Follow Joe Bondy-Denomy:
About Acrigen Biosciences: Acrigen Biosciences is dedicated to making gene editing safe.
Ilya Rachman
Co-Founder & CEO of Immix Biopharma
Ilya Rachman is a physician-scientist and clinical faculty at UCLA. He received both his MD and PhD in neuroscience and cell biology from the University of Illinois-Chicago, and his MBA from UCLA Anderson. Previous to Immix, Dr. Rachman founded a clinical research organization that conducted clinical trials on behalf of pharmaceutical companies. He has completed several clinical trials as a Principal Investigator and is a co-inventor of Immix’ platform therapeutic technology.
Follow Ilya Rachman:
About Cedars Sinai Medical Center, Immix Biopharma: Immix Biopharma is a biotech company that develops treatments for cancer and other inflammation-driven diseases.
Chih-Ping Liu
Co-Founder of Bolt Biotherapeutics
Chih-Ping Liu is the Founder, Managing Director, and the Chairman of the Board of Directors at Angarus Therapeutics. He is also serving as a co-founder at Bolt Therapeutics. He received his Ph.D. degree in Genetics from the University of Wisconsin-Madison.
Follow Chih-Ping Liu:
About Angarus Therapeutics, Bolt Biotherapeutics: Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
Edgar Engleman
Founder of Bolt Biotherapeutics
Follow Edgar Engleman:
About Bolt Biotherapeutics: Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
Bárbara Kunde Minuzzi
Co-Founder and Managing Partner of Babel Ventures
Bárbara is a financial advisor to ultra high net worth families and has singlehandedly raised over $250 million for real estate and high tech companies in both Brazil and the US. Starting her career as an entrepreneur in fashion in Brazil, Bárbara moved towards investment management early in her career by co-founding INVESTHAUS with Daniela and moving to Miami. She soon became an advisor and angel investor to several high-profile startups, such as Spinn Coffee, CALA, OccamzRazor, Cue and Singu. In 2016, Bárbara moved to San Francisco to start her own venture firm, BABEL Ventures. With extensive experience in diversifying investments and building strategic portfolios, Bárbara is the chief networker with founders and VC firms in Silicon Valley.
Follow Bárbara Kunde Minuzzi:
About Babel Ventures: Babel Ventures is an early stage VC fund backing driven, impact-oriented entrepreneurs in Silicon Valley.
Peter Gassner
Founder and CEO of Veeva
Peter is responsible for the overall direction and management of Veeva Systems. In 2010, Peter was named to the PharmaVOICE 100, which recognizes the 100 most influential people in the life sciences industry. Peter is a twenty year veteran of the software industry. Prior to founding Veeva, Peter was Senior Vice President of Technology at salesforce.com where he had responsibility for building the salesforce.com platform including product, marketing and developer relations. During Peter’s tenure, salesforce.com completed its public offering and grew the technology into the most successful SaaS platform in the industry. Before salesforce.com, Peter was with PeopleSoft for 9 years as both Chief Architect and General Manager of PeopleTools. Peter led a team of over 450 professionals who provided the development, strategy, marketing and customer support for PeopleSoft’s technology platform. PeopleTools was widely regarded in the industry as the best application platform of its day. Peter began his career with IBM in relational database development and research at IBM Silicon Valley Lab and then at IBM Almaden Research Center where he had the privilege of working closely with some of the inventors of relational database technology. Peter holds a Bachelor of Science degree in Computer Science from Oregon State University.
Follow Peter Gassner:
About Veeva: Veeva Systems is a provider of cloud-based business solutions for the global life sciences industry.
Michael Snyder
Founder of Q Bio
Stanford W. Ascherman Professor and Chair, Department of Genetics and Director, Center for Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of-the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. Snyder is a cofounder of several biotechnology companies, including Protometrix (now part of Life Tehcnologies), Affomix (now part of Illumina), Excelix, Personalis and founder of Q, and he presently serves on the board of a number of companies. Dr Snyder is the author of the book: Genomics and Personalized Medicine: What Everyone Needs to Know
Follow Michael Snyder:
About Metagenomix, Q Bio: On a mission to build the first Clinical Digital Twin Platform and make it accessible to everyone
Ben Hindson
CSO, CO-Founder & President of 10X Genomics
Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, Hindson was Co-founder and Chief Scientific Officer of Quantalife, a privately-held life sciences company that developed and commercialized a droplet digital PCR platform, until its sale to Bio-Rad in 2011. From 2002 to 2008, he served in various positions of increasing responsibility at Lawrence Livermore National Laboratory, in the Chemical and Biological Weapons Non-proliferation Program. He has published extensively in his field and holds many patents for assays and instrumentation. Hindson earned his BSc in Chemistry in 1998 and his PhD in Chemistry in 2001 from Deakin University, Australia.
Follow Ben Hindson:
About 10X Genomics: 10X Genomics ELV solutions and security systems company that provides an innovative genomics platform.
Noga Leviner
Co-Founder & CEO of PicnicHealth
Noga was inspired to create Picnic after being diagnosed with an autoimmune disease and struggling to keep track of her own health data. She had previously co-founded Lumni USA, where she raised and deployed the first US investment fund to help underserved students access low-risk, equity-style student loan products. She has been a regular speaker and consultant on financial innovation for the underbanked and, more recently, an advocate for patient data access in the healthcare system. Noga has a BA from Stanford where she studied Human Biology and Economics. She can regularly be found spacing out while trying to meditate.
Follow Noga Leviner:
About PicnicHealth: PicnicHealth helps patients easily access their medical records and gives them the opportunity to contribute data to medical research.
Troy Astorino
Co-Founder & CTO of PicnicHealth
Follow Troy Astorino:
About PicnicHealth: PicnicHealth helps patients easily access their medical records and gives them the opportunity to contribute data to medical research.
Mark Herrema
Co-Founder & CEO of Newlight Technologies
As CEO and co-founder of Newlight, Mr. Herrema has over a decade of industrial experience in chemical, biological, and process engineering, intellectual property development, polymer functionalization, private equity finance, and strategic business development. Mr. Herrema has invented a range of proprietary carbon capture and conversion systems and materials, receiving numerous associated US and international patents, steering Newlight through multiple private placement offerings, executing a range of strategic partnerships, and leading the engineering, construction, optimization, and expansion of Newlight’s carbon capture platform. Mr. Herrema graduated magna cum laude High Honors from Princeton University with a Bachelor of Arts degree in Politics and Political Theory, with additional work in Physics, Mathematics, and Chemistry.
Follow Mark Herrema:
About Newlight Technologies: Newlight Technologies is a biotechnology company producing advanced sustainable materials.
Daniel Levitt
Founder & CEO of Bioz
Daniel Levitt is the CEO & Founder at Bioz.
Follow Daniel Levitt:
About Bioz, StartX (Stanford-StartX Fund), Stemrad: Bioz is a disruptive startup at the intersection of information technology and scientific research.
Dr. Karin Lachmi
Founder & CSO of Bioz
Dr. Karin Lachmi is the Chief Scientific Officer & Founder at Bioz.
Follow Dr. Karin Lachmi:
About Bioz, StartX (Stanford-StartX Fund): Bioz is a disruptive startup at the intersection of information technology and scientific research.
Pratik Shah
Executive Chairman & Co-Founder of Design Therapeutics
Pratik Shah is the Co-Founder and Executive Chairman of Design Therapeutics.
Follow Pratik Shah:
About CNS Therapeutics (Old), Design Therapeutics: Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Cameron Teitelman
Founder, Chairman, and head of admissions and oversee investment vehicles of StartX (Stanford-StartX Fund)
Cameron Teitelman is the Founder and Chairman of StartX, a 501 (c)(3) nonprofit that runs an accelerator for Stanford affiliated entrepreneurs. Under his management, StartX has supported more than 1,100+ founders building 500+ companies. StartX companies have raised over $3.3B to date. In 2013, the Stanford-StartX Fund was launched. To date, SSF has invested in 250 StartX companies across 400+ rounds, investing $130 million in capital.
Follow Cameron Teitelman:
About StartX (Stanford-StartX Fund): StartX is an educational non-profit that helps Stanford’s top entrepreneurs.
Dan Ha
Co-Founder, Sr. Managing Director of StartX (Stanford-StartX Fund)
Follow Dan Ha:
About StartX (Stanford-StartX Fund): StartX is an educational non-profit that helps Stanford’s top entrepreneurs.
Mark McKenna
Founder, President and CEO of Prometheus Biosciences
Mark McKenna currently works as President and Chief Executive Officer at Prometheus Biosciences. He previously worked at Bausch + Lomb as Senior Vice President and General Manager.
Follow Mark McKenna:
About Prometheus Biosciences: Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Craig Taylor
Co-Founder & General Partner of Alloy Ventures
Craig C. Taylor has been an active venture capitalist since 1977, and co-founded Alloy Ventures with John Shoch in 1996. At Alloy, he focuses on investments in laboratory instrumentation, diagnostics and cleantech, especially green-focused companies that sit at the intersection of biotech, nanotech and IT. Craig is a veteran venture capital investor and expert in technology transfer from leading research institutions. Before co-founding Alloy Ventures, he worked at Asset Management Co., which he joined in 1977. Previously, Craig worked in the Office of Technology Licensing at Stanford University from 1975 to 1977. He is a past member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford (1977). Craig serves on the board of directors of ForteBio, Labcyte, Optimedica, Zyomyx, and KFx Medical. Craig has led successful investments in, and served on the boards of, dozens of leading life science companies. He was a founding board member of Applied Biosystems, the pioneering biotechnology company founded in 1981 that was later became a division of Applera and was recently sold for $6.7 billion to Invitrogen Corp. He was also a founding board member of Adeza Biomedical, a woman’s health company that completed a public offering on Nasdaq in 2004 and was later acquired by Cytec. He also served on the board of Lynx Therapeutics, a provider of genetic analysis tools for biological research that completed an IPO on Nasdaq in 2000, and later merged with Solex Ltd., before it was acquired by Illumina for $600 million 2006.
Follow Craig Taylor:
About Alloy Ventures: Alloy Ventures is an early stage venture capital firm that invests in the areas of life sciences, information technology, and cleantech.
Martyn Gross
Co-Founder & CEO of Zerigo Health
Advisor at Cooler Heads Care & Chief Business Officer at Mindera.
Follow Martyn Gross:
About Dthera Sciences, MiNDERA Corporation, Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Remo Qajar
Co-Founder of Zerigo Health
Remo Qajar is the Co-Founder and Chief Innovation Officer at Skylit Medical. Remo’s postgraduate career as an academic researcher and trained Surgeon at the Yale School of Medicine led him to invent a number of medical devices, from implantable respiratory diaphragms to orthopedic and wound care products, some of which have been spun-off into companies. Remo is the founder of InQMEDS LLC. an accelerator of growth for early stage life-science products.
Follow Remo Qajar:
About Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Chris Varma
Founder, President & CEO of Frontier Medicines
Chris joined Flagship in 2007 as Partner and focuses primarily on Life Science investments. He came to Flagship with significant management experience in clinical development, regulatory strategy, business development, sales, and marketing in the pharmaceutical industry. Prior to Flagship, Chris was with Novartis Pharmaceuticals since 2004 where he served most recently as Director of the Tekturna (aliskiren) marketing team responsible for all Medical Marketing, Medical Strategy, and Professional Promotions activities in the U.S. Chris also oversaw Tekturna�s extensive clinical development programs, and played a key role in the FDA approval, CMS reimbursement coverage approval, and successful commercial launch of Tekturna in early 2007. Previously at Novartis, Chris was Director of Business Development & Licensing where he identified several in-licensing opportunities and drove key transactions. Prior to that, Chris focused on corporate strategy working directly with the Novartis Pharma CEO in Basel, Switzerland. Before Novartis, Chris was a consultant for Millennium Pharmaceuticals working on special projects in the Personalized Medicine Group. Before Millennium, Chris worked for the US Food and Drug Administration (FDA) in the Office of Combination Products coordinating and managing reviews across the major Centers. Early in his career he co-founded Epitrope Corporation, a company that developed server-side solutions for wireless telecom carriers.
Follow Chris Varma:
About Frontier Medicines, Harvard Medical School, Vision Medicines: Frontier Medicines is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery.
Ben Chiarelli
Founder and CEO of Cellibre
Ben Chiarelli is the founder and CEO of Cellibre. He is also the founder and managing partner at Divitempus Ventures. Ben earned his MBA from Carnegie Mellon University’s Tepper School of Business and his B.S. in mechanical engineering from Case Western Reserve University.
Follow Ben Chiarelli:
About Cellibre: Cellibre turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale.
Fabian Gerlinghaus
Co-Founder & CEO of Cellares
Fabian Gerlinghaus is the CEO and Co-Founder of Cellares.
Follow Fabian Gerlinghaus:
About Cellares: Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
Wenbin Jiang
Co-Founder and CEO of Cytek Biosciences
Wenbin Jiang is a co-founder of Cytek Biosciences, Inc. and a seasoned entrepreneur and inventor. E2O communications was the first company he cofounded in late 1990s, which was acquired by JDS Uniphase in 2004. He is an inventor of more than 90 US patents and an author of 4 book chapters and more than 50 peer reviewed technical papers.
Follow Wenbin Jiang:
About Cytek Biosciences: Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.
Ming Yan
Co-Founder and CTO of Cytek Biosciences
Ming Yan is a co-founder of Cytek Biosciences, Inc. with over 20 years of R&D experience in leadership and innovation. Prior to Cytek, Ming Yan held research and development positions at AT&T Bell Laboratories, Lawrence Livermore National Labs and BD Biosciences. He is one of the thought-leaders in flow cytometry instrumentation and standardization. Ming Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.
Follow Ming Yan:
About Cytek Biosciences: Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.
Jed Dean
Co-Founder of Zymergen
At Zymergen, Jed is responsible for building and operating the robotic workflows for genome engineering and high throughput screening. Prior to his work at Zymergen, he developed technology and automation for life sciences at Amyris and at the Stanford Genome Technology Center. He earned his bachelor’s degree in molecular biology from Purdue University and has a PhD in biochemistry from the Stanford University School of Medicine.
Follow Jed Dean:
About Zymergen: Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
Zach Serber
Co-Founder of Zymergen
Zach Serber is a founder at Zymergen. He was previously the Director of Biology at Amyris and the Principal Investigator on a DARPA contract to develop advanced tools for synthetic biology. Dr. Serber has 15 peer-reviewed publications, 5 filed patents, and worked as a research fellow at Stanford University Medical School. He has a PhD in Biophysics from UCSF, an MSc in Neuroscience from the University of Edinburgh, and a BA from Columbia University. He lives on a sailboat in Sausalito with his wife and daughter.
Follow Zach Serber:
About Zymergen: Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
James H. Bullard
Co-Founder and CTO of Pendulum Therapeutics
James Bullard is a Computational Biologist and Biostatistician with extensive experience in analyzing complex genomic systems. Prior to co-founding Whole Biome, Jim served as a Senior Staff Scientist at Pacific Biosciences. Jim, completed his Ph.D. in Biostatistics with a focus in Computational and Genomic Biology at the University of California, Berkeley and his B.A. in Computing and Information Systems at Northwestern University.
Follow James H. Bullard:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Colleen Cutcliffe
Co-Founder and CEO of Pendulum Therapeutics
Colleen Cutcliffe is the Co-Founder and CEO of Pendulum Therapeutics.
Follow Colleen Cutcliffe:
About American Diabetes Association, California Life Sciences Association, Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
John S. Eid
Co-Founder and CSO of Pendulum Therapeutics
John Eid is a Biophysicist who has led fundamental technology development for over a decade. His research areas include advanced microscopy, single molecule detection and analyses, automated data acquisition system development, biophysical system modeling, genome sequencing applications and bioinformatics. Prior to co-founding Whole Biome, John served as a Principle Scientist at Pacific Biosciences. He joined the company shortly after it was founded and created, developed and applied its core sequencing technology from its incipient stages through commercialization. John completed his postdoctoral research at the Roland Institute at Harvard University, his Ph.D. in Biophysics and Computation Biology at the University of Illinois, Urbana Champaign, and his B.S. in Applied and Engineering Physics from Cornell University.
Follow John S. Eid:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Benjamine Liu
CEO and Co-Founder of TrialSpark
Benjamine Liu is the CEO and Co-Founder of TrialSpark. He is a former Computational Biologist at Translational Neuroscience and Dementia Research Group and ChenPloktin Lab, Department of Neurology. Mr. Liu graduated from Yale University with a bachelor of science in Biology and earned a master of philosophy in Computational Biology, Department of Applied Mathematics and Theoretical Physics at Cambridge University and received a doctor of philosophy in Computational Biology and Psychiatry at the University of Oxford.
Follow Benjamine Liu:
About ResearchWe, TrialSpark: TrialSpark is a technology company that helps bring treatments to patients faster by reimagining how clinical trials are run.
Stephen Kaldor
Co-Founder and Chairman of XinThera
Steve is a Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery. Steve was CEO of Ambrx from 2007-2010 and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly as both a researcher and Director. A chemist by training, Steve is a co-inventor of ten therapeutic compounds that have entered the clinic including Viracept, a marketed AIDS medication, and Nesina, a marketed diabetes medication. Steve also serves as an independent board member for various companies including Furiex (2010 – current), Amira (2008 through 2011 acquisition by BMS) and Anaphore (2008 – 2011). He received a PhD from Harvard University and a BA from Columbia University.
Follow Stephen Kaldor:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Nancy Yu
Co-Founder & CEO of AllStripes
Nancy previously led Corporate Development at 23andMe, the largest consumer genetics company. She worked on 23andMe’s next generation sequencing platform, drug discovery strategy, and business development programs. Before that, she worked on Wall Street as a biopharma investment banker. Nancy began her career doing genetics research at the University of Pennsylvania. She’s passionate about bridging the gap between patients and industry to make drug R&D cheaper, faster, and better.
Follow Nancy Yu:
About AllStripes: AllStripes is a healthcare technology company that accelerates drug development and research for the treatment of rare diseases.
Sophia Wang
Co-Founder & Chief of Staff and Culture of MycoWorks
Sophia Wang leads MycoWorks with expertise in strategic fundraising, communications, and project management. As a former Program Director, she was responsible for materials procurement, resource allocation, and oversight of vendor relations and physical infrastructure. She has produced large-scale arts and science events at San Francisco cultural institutions that include Yerba Buena Center for the Arts, the Exploratorium, and California College of the Arts. As a Development Director, she has led successful capital campaigns for New York and Bay Area-based educational initiatives. Sophia earned a Ph.D. in English Literature from U.C. Berkeley and is active in the Bay Area performing arts community as a dancer and choreographer. Her deep interest in mycelium materials and biomimetic design stems from a lifelong immersion in her family’s ongoing professional research in molecular cell biology and mycology.
Follow Sophia Wang:
About MycoWorks: MycoWorks is a biotech company that delivers commercially viable non-plastic and non-animal materials to the market.
Carlito Lebrilla
Co-Founder of Evolve Biosystems
Carlito B. Lebrilla is a Distinguished Professor at the University of California, Davis in the Department of Chemistry and Biochemistry and Molecular Medicine in the School of Medicine. He received his BS degree from the University of California, Irvine and Ph.D. from the University of California, Berkeley. He was an Alexander von Humboldt Fellow and a NSF-NATO Fellow at the Technical University in Berlin. He returned to the UC Irvine as a President’s Fellow and has been at UC Davis since 1989. He has served as Chair of the Chemistry Department. His research is in Analytical Chemistry, primarily mass spectrometry with applications to clinical glycomics and biofunctional food. He has over 320 peer-reviewed publications. He is also co-editor of Mass Spectrometry Reviews and has been on the editorial board of Molecular and Cellular Proteomics, Mass Spectrometry Reviews, Journal of American Society for Mass Spectrometry, European Mass Spectrometry, and International Journal of Mass Spectrometry.
Follow Carlito Lebrilla:
About Evolve Biosystems, InterVenn: Evolve Biosystems specializes in providing microbiome-based products designed to develop, restore, and maintain.
Daniela Barile
Co-Founder of Evolve Biosystems
Daniela Barile is Associate Professor at the University of California Davis. She received her degrees in the area of Pharmaceutical Chemistry and Food Science from the Piemonte Orientale University (Italy). Her research, focused at the nexus of food, health, and the environment, aims to understand food bioactive compounds formation, their recovery from food production side streams, and their specific interactions within the human body. Her lab utilizes analytical platforms based on mass spectrometry to investigate foods and a range of relatively untapped organic waste streams for valuable, healthful bioactive compounds (such as free oligosaccharides, peptides, glycoproteins and glycolipids). Her approach of sequential molecular deconstruction of food streams is generating valuable bioinformatic libraries of source materials and the underlying biological and processing conditions that give rise to their formation/preservation.
Follow Daniela Barile:
About Evolve Biosystems, University of California Davis, University of California Davis: Evolve Biosystems specializes in providing microbiome-based products designed to develop, restore, and maintain.
Sandra Horning
Co-Founder of EQRx
Dr. Sandra Horning, M.D. is the Co-Founder of EQRx. She has been Chief Medical Officer and Head of Global Product Development at Roche Holding AG since January 13, 2014. Dr. Horning has been Global Head of Clinical Development Hematology & Oncology and Senior Vice President of Genentech, Inc., since September 2009. Dr. Horning is responsible for leading the medical and scientific strategies for the global clinical development portfolio in oncology. Dr. Horning leads the disease biology leadership team for oncology/hematology. In addition, Dr. Horning leads and manage Genentech’s team of oncology clinical scientists. She has more than 35 years of experience, with a focus on oncology.
Follow Sandra Horning:
About EQRx, Roche Holdings, Australia: EQRx is a biotechnology company that focuses on re-engineering the process of drug discovery to make them affordable.
Maneesh Jain
CEO and Co-Founder of Mirvie
Maneesh Jain currently works as Chief Executive Officer and the Founder of Mirvie. He previously worked at Cirina (Grail) as CEO and President.
Follow Maneesh Jain:
About Mirvie: Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
Vivian Qu
CEO & Founder of ViaeX
Vivian Qu is a dedicated professional operating within the material science and biotech venture space in Silicon Valley. She is the CPO at ORA Nano Mask, and she founded ViaeX Technologies, Inc. in 2016 to contribute to the advancement of our society through sustainable technological developments. For her work across her career, Vivian Qu has earned recognition as the recipient of the Dow Chemical SISCA Award, the Clinton Global Initiative Award, and the Fung Fellowship. Additionally, she received the NSF Innovation Corp Grant and the Big Ideas Berkeley – Energy and Alternative Resources Prize. Vivian was also recognized in the Pulse by Business Insider for her work as a graduate from the University of California, Berkeley.
Follow Vivian Qu:
About Tidal Vision, ViaeX: ViaeX creates biological nanofiltration systems for water and air which are 400% more efficient than current solutions.
Moran Shochat Snir
Co-Founder & CEO of Clear Genetics
Follow Moran Shochat Snir:
About Clear Genetics, Invitae: Clear Genetics is a digital health company dedicated to the thoughtful integration of genetics into routine patient care.
Guy Snir
Co-Founder & COO of Clear Genetics
Follow Guy Snir:
About Clear Genetics, Invitae: Clear Genetics is a digital health company dedicated to the thoughtful integration of genetics into routine patient care.
Chris K. Achar
Founder & CEO of GenZum Life Sciences
Follow Chris K. Achar:
About GenZum Life Sciences: Genzum Life Sciences is a globally integrated Generic Pharmaceutical Product Development and Out-licensing company, based in Los Angeles
Benjamin Cravatt
Director and Co-Founder of Boundless Bio
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Follow Benjamin Cravatt:
About Boundless Bio, Vividion Therapeutics: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Jonathan Lim
Chairman & Co-Founder of Boundless Bio
Jonathan Lim is Founder of Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company that is a portfolio company of City Hill Ventures, LLC, a health care investment firm that he founded in 2010. Jonathan is also a Board Director of Bionomics Ltd (ASX: BNO). Prior to Ignyta, Jonathan’s experience includes Chairman, CEO and co-founder of Eclipse Therapeutics, Inc.; President and CEO of Halozyme Therapeutics, Inc. (Nasdaq: HALO); management consultant at McKinsey; NIH Postdoctoral Fellow at Harvard Medical School; and general surgery resident at New York Hospital-Cornell. In addition to serving on the Bio-X Advisory Council, Jonathan has been actively involved with his class reunion campaigns and other Stanford related activities. Jonathan has a B.S and M.S. from Stanford in Biological Sciences, an M.D. from McGill University and an M.P.H. from Harvard. Jonathan lives in San Diego with his wife, Dr. Conyee Tsai Lim (BA ’93), and their three children.
Follow Jonathan Lim:
About ARCH Venture Partners, Boundless Bio, City Hill Ventures, Erasca: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Anatoly Chubais
CEO & Founder of RUSNANO
Anatoly Chubais is the CEO & Founder of RUSNANO.
Follow Anatoly Chubais:
About RUSNANO: Rusnano is a joint-stock company aimed at commercializing developments in the nanotechnology industry.
Patrick Enright
Founder and Managing Director of Longitude Capital
Patrick Enright is the Board Member at Esperion Therapeutics.He has served as a Member Of Board Of Directors since April 2013.He is also the Managing Director, Longitude Capital Management Co., LLC. Patrick is a founder of Longitude Capital Management Co., LLC, a venture capital firm focused on investments in biotechnology, and has served as its Managing Director since 2007. From 2002 through 2006, Patrick was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, Patrick was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately held and publicly traded biotechnology companies. Patrick is a director of a number of companies including,Corcept Therapeutics, Inc. (NASDAQ: CORT),Jazz Pharmaceuticals plc (NASDAQ: JAZZ).Patrick earned an M.B.A. from the Wharton School of Business at the University of Pennsylvania.B.S. in Biological Sciences from Stanford University.
Follow Patrick Enright:
About Longitude Capital: Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Tyler Shultz
Co-Founder & CEO of Flux Bioscience
Tyler Shultz is an entrepreneur fostering innovation in healthcare.
Follow Tyler Shultz:
About Ethics in Entrepreneurship, Flux Bioscience: Flux Biosciences is a company spun out of Stanford University, where the technology used to read and write computer hard drives .
Shan X Wang
Co-Founder of Flux Bioscience
Follow Shan X Wang:
About Flux Bioscience: Flux Biosciences is a company spun out of Stanford University, where the technology used to read and write computer hard drives .
J. Jean Cui
Scientific Founder & Board Member of Turning Point Therapeutics
J. Jean Cui, Ph.D. is a renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at Big Pharma and biotech companies (Pfizer, Pharmacia/SUGEN, etc.). Jean is the lead inventor of Pfizer’s precision oncology medicine, crizotinib, brand named XALKORI®. She created the drug’s novel chemical scaffold based on co-crystal structure and designed the final clinical compound crizotinib. XALKORI® was fast track approved by US Food and Drug Administration on August 26, 2011 for ALK positive late stage non-small cell lung cancer (NSCLC). In addition to the invention of crizotinib, Jean worked on several other oncology projects, including SUTENT®. She also created the clinical c-MET specific inhibitor PF-04217903 and designed the ALK second generation clinical compound PF-06463922. Her exceptional achievements in drug discovery and development have earned her many prestigious awards which include: the 38th National Inventor of the Year by Intellectual Property Owners’ Association (2011); Woman Worth Watching by Diversity Journal (2012); American Chemical Society Hero of Chemistry (2013); Pfizer Worldwide R&D Achievement Awards (2006 and 2012); Pfizer Innovation Award (2011); CABS K. Fong Award for Life Sciences (2013). Her story of crizotinib invention was featured in a Wall Street Journal article titled “Drug Discovery Gets an Upgrade” on April 16, 2012.
Follow J. Jean Cui:
About BlossomHill Therapeutics, Turning Point Therapeutics: Turning Point Therapeutics is a structure-based drug design pharmaceutical company.
Alice Zhang
Co-Founder & CEO of Verge Genomics
CEO and Co-founder at Verge Genomics; Angel Investor in Tech-Enabled Bio
Follow Alice Zhang:
About Verge Genomics: Verge Genomics uses machine learning and human genomics to accelerate drug discovery.
Josh Tetrick
Co-Founder & CEO of Eat Just
Josh is the CEO & Co-Founder of Eat Just, Inc., a San Francisco-based company on a mission to bring delicious, accessible, healthier and more sustainable food to everyone, everywhere. Prior to founding the company, Tetrick led a United Nations business initiative in Kenya and worked for both former President Clinton and Liberian President Ellen Johnson Sirleaf. As Fulbright Scholar, Tetrick taught schoolchildren in Nigeria and South Africa and is a graduate of Cornell University and the University of Michigan Law School. Tetrick has been named one of Fast Company’s “Most Creative People in Business,” Inc.’s “35 Under 35” and Fortune’s “40 Under 40.”
Follow Josh Tetrick:
About 33needs, Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Guy Miller
Chairman, CEO & Co-Founder of Edison Pharmaceuticals
Guy Miller, MD, PhD is the co-founder of Edison Pharmaceuticals, and has served as Chairman and Chief Executive Officer of the Board since 2005. Prior to founding Edison, he founded Galileo Pharmaceuticals, a biopharmaceutical company, and was its Chairman and CEO from 1995-2005. Dr. Miller holds an MD from the Medical College of Pennsylvania and a PhD in chemistry from the University of Virginia. He completed his surgical internship at the University of Chicago, and a residency in anesthesiology and critical care medicine at Johns Hopkins. Dr. Miller completed a fellowship in multidisciplinary critical care medicine at Johns Hopkins, where he was on the faculty as an Assistant Professor until 1996. He is currently an attending physician in medical-surgical critical care medicine at Stanford University-PAVAMC.
Follow Guy Miller:
About Ampere Life Sciences, BioElectron Technology Corporation, Edison Pharmaceuticals, Stanford University School of Medicine: Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Alex Furman
Co-Founder & Head of Organizational Development of Invitae
Alex co-founded Locus Development after leading the software engineering effort at Navigenics. Prior to that, he spent many years developing automated trading systems and financial planning software. A born-and-bred programmer, Alex grew up playing with computers that took up entire rooms and were orders of magnitude less powerful than the smartphone he now carries in his pocket.
Follow Alex Furman:
About Invitae: Invitae is a medical genetics company that bring comprehensive genetic information into mainstream medicine to improve healthcare.
John Kuriyan
Co-Founder of Nurix Therapeutics
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Follow John Kuriyan:
About Nurix Therapeutics: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Arthur Weiss
Co-Founder of Nurix Therapeutics
Arthur Weiss, M.D., Ph.D., is a pioneer in cell biology and signal transduction. Dr. Weiss is a Howard Hughes Medical Institute Investigator and Ephraim P. Engleman Distinguished Professor, University of California San Francisco. He has previously served as the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. Dr. Weiss received his B.A. at the Johns Hopkins University and his M.D. and Ph.D. from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
Follow Arthur Weiss:
About Nurix Therapeutics, University of California, San Francisco, University of California, San Francisco: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Michael Rape
Co-Founder of Nurix Therapeutics
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
Follow Michael Rape:
About Nurix Therapeutics: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
